Halo-Bio RNAi Therapeutics Analysis
What is Halo-Bio RNAi Therapeutics?
Halo-Bio RNAi Therapeutics develops a patented multivalent RNAi platform to enable multi-gene suppression for treating disease. The platform features a self-forming RNA core and programmable particle shells for targeted delivery. It is being applied to develop treatments for viral infections, including a specific project targeting SARS-2 with AmpliVIR RNA. The company is in early-stage development with a focus on RNA delivery and biopharmaceuticals.
Location
Seattle, United States
Employees
1-10
Founded
2008
Product Features & Capabilities
- Multivalent RNAi trigger (MV-RNA) for multi-gene suppression
- Self-forming RNA core (40 nm spheres) with targeted gene silencing
- Programmable particle shells using aptamer-driven proteins for tissue-specific delivery
- AmpliVIR RNA for SARS-2 self-inactivation
- RNA nanoparticle formulations for intracellular delivery
Use Cases
Target multiple disease genes simultaneously with MV-RNA; Deliver RNAi therapeutics to specific organs using programmable shells; Suppress SARS-2 viral expression in infected cells with AmpliVIR RNA; Develop nasal spray or inhalation treatments for early-stage viral infections; Design RNA nanoparticles for targeted delivery to liver, kidney, brain, or other tissues
Other Considerations
Pivoting research toward SARS-2 treatment with AmpliVIR RNA; Patented multivalent RNAi platform; Focus on programmable nanoparticle delivery; Early-stage development in RNA delivery and biopharmaceuticals; Research collaboration opportunities with scientists and institutions
See something that needs updating? Suggest edits to this profile.